Literature DB >> 8666020

Receptor binding profile of cyclazosin, a new alpha 1B-adrenoceptor antagonist.

D Giardinà1, M Crucianelli, C Melchiorre, C Taddei, R Testa.   

Abstract

The binding profile of cyclazosin, a new prazosin-related alpha 1-adrenoceptor antagonist, at alpha 1-, alpha 2-adrenoceptors, dopamine D2 and 5-HT1A receptors was compared to that of 5-methylurapidil, spiperone, risperidone and other prazosin-related ligands. In addition, cyclazosin was investigated at native and cloned alpha 1-adrenoceptor subtypes. Cyclazosin showed high specificity for alpha 1-adrenoceptors and a 10-15-fold selectivity for alpha 1B (alpha 1b)-adrenoceptors with respect to the alpha 1A (alpha 1a) subtype (pKi values of 9.23-9.57 and 8.18-8.41, respectively). However, it failed to discriminate between cloned alpha 1b and alpha 1d-adrenoceptors (pKi values of 9.23 and 9.28, respectively).

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8666020     DOI: 10.1016/0014-2999(95)00471-7

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  4 in total

Review 1.  Advances in the design and synthesis of prazosin derivatives over the last ten years.

Authors:  Andreas Desiniotis; Natasha Kyprianou
Journal:  Expert Opin Ther Targets       Date:  2011-12-13       Impact factor: 6.902

2.  Pharmacophore development for antagonists at alpha 1 adrenergic receptor subtypes.

Authors:  J B Bremner; B Coban; R Griffith
Journal:  J Comput Aided Mol Des       Date:  1996-12       Impact factor: 3.686

3.  Syntrophin isoforms play specific functional roles in the α1D-adrenergic receptor/DAPC signalosome.

Authors:  John S Lyssand; Kyung-Soon Lee; Mia DeFino; Marvin E Adams; Chris Hague
Journal:  Biochem Biophys Res Commun       Date:  2011-08-09       Impact factor: 3.575

4.  Crystal structure of the α1B-adrenergic receptor reveals molecular determinants of selective ligand recognition.

Authors:  Lena Morstein; Matthias Schuster; Mattia Deluigi; Christoph Klenk; Lisa Merklinger; Riley R Cridge; Lazarus A de Zhang; Alexander Klipp; Santiago Vacca; Tasneem M Vaid; Peer R E Mittl; Pascal Egloff; Stefanie A Eberle; Oliver Zerbe; David K Chalmers; Daniel J Scott; Andreas Plückthun
Journal:  Nat Commun       Date:  2022-01-19       Impact factor: 14.919

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.